fbpx

Nyheder

Lundbeckfonden Ventures nyheder

Lund, Sweden, 08:45 CET, December 9 2019 BONESUPPORTTM, an emerging leader in orthobiologics for the management of bone injuries, today announced the publication of the Level I clinical study CERTiFy in the highly ranked Journal of Bone and Joint Surgery. The authors concluded that CERAMENT® BVF was as good as autograft with regard to both...
November 25, 2019 at 8:49 AM CET Veloxis to Host Conference Call Following Asahi Kasei Group’s Announcement of a Recommended Conditional Voluntary Public Offer for Veloxis As announced in Company Release no. 18/2019, Veloxis Pharmaceuticals A/S (OMX: VELO) (”Veloxis” or the ”Company”) and Asahi Kasei Pharma Denmark A/S (”Asahi Kasei Pharma Denmark A/S” or the...
November 25, 2019 at 8:29 AM CET Asahi Kasei Group Announces a Recommended Conditional Voluntary Public Offer for Veloxis Veloxis Pharmaceuticals A/S (OMX: VELO) (”Veloxis” or the ”Company”) and Asahi Kasei Pharma Denmark A/S (”Asahi Kasei Pharma Denmark A/S” or the ”Offeror”) have today entered into a transaction agreement (the ”Transaction Agreement”) pursuant to which...
Lund, Sweden, 16:00 CET, November 12 2019 – BONESUPPORT™ an emerging leader in orthobiologics for the management of bone injuries, announces changes in its leadership team that will take place November 18, 2019. Fergus MacLeod starts in the position as the company´s General Manager & Executive Vice President Commercial Operations EUROW. Fergus MacLeod has more...
SNF472 significantly reduced progression of cardiovascular calcification in patients with end stage kidney disease (ESKD) receiving hemodialysis SNF472 treated patients had coronary artery calcium (CAC) volume score progression of 11% from baseline versus 20% in patients receiving placebo (P=0.016) SNF472 was well tolerated Results are remarkable as they have been achieved in patients who continued to...
Monday 18 November at 11:00 ET /16:00 GMT / 17:00 CET Sanifit will host a webcast on Monday November 18 at 11am ET / 5pm CET / 4pm GMT on the results of the international Phase 2b CaLIPSO study of lead candidate SNF472 in patients with end stage kidney disease (ESKD) on hemodialysis. Joan Perelló, CEO and Alexander M....
Lund, Sweden, 7 November 2019 08.00 am CET, – BONESUPPORT HOLDING AB (publ), an emerging leader in orthobiologics for the management of bone voids, today publishes the interim report for the third quarter 2019. BONESUPPORT’S BEST QUARTER EVER “Sales in the quarter are our highest ever, with strong growth in both Europe and the US....
Lund, Sweden, 12:00 pm CET, 31 October 2019 – BONESUPPORT HOLDING AB (publ), an emerging leader in orthobiologics for the management of bone voids. During October, the number of shares and votes in BONESUPPORT HOLDING AB (publ) has increased with 8,125 due to the exercise of warrants. As of 31 October 2019, the number of...
Cambridge, UK and Indianapolis, US – 30 October 2019: Acacia Pharma Group plc (the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialisation of new nausea and vomiting treatments for surgical and cancer patients, announces that application has been made to Euronext Brussels for the admission of the 940,442 Ordinary Shares of...
1 2 3 61

Lundbeckfonden Ventures

Nyheder

BONESUPPORTTM CERTiFy STUDY ON CERAMENT ® BONE VOID FILLER NOW PUBLISHED IN THE JOURNAL OF BONE AND JOINT SURGERY
9. december 2019
Veloxis to Host Conference Call Following Asahi Kasei Group’s Announcement of a Recommended Conditional Voluntary Public Offer for Veloxis
25. november 2019
Asahi Kasei Group Announces a Recommended Conditional Voluntary Public Offer for Veloxis
25. november 2019